Raptiva (efalizumab)
- Region
- 🇪🇺 EU
- Active substance
- efalizumab
- Company
- Serono Europe Limited
- Status
- Withdrawn
- Therapeutic area
- Psoriasis
- EU approval
- Mon 20 Sep 2004
- Application
- EMEA/H/C/000542
- ATC
- L04AA21
- Official record
- www.ema.europa.eu
Indication
Treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA (see section 5.1 - Clinical Efficacy).
Regulatory milestones
No milestones recorded in the last year.
Follow Raptiva
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.